OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.